Track Ascendis Pharma A/S — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Ascendis Pharma A/S ASND · Stock Open Ascendis Pharma A/S in new tab

275.39 USD
P/E
17.53
EPS
15.71
P/B
10.69
ROE
132.20
Target Price
308.32 USD
Loading chart...
Key Metrics
Earnings dateFeb. 10, 2027
P/E17.53
EPS15.71
Book Value25.75
Price to Book10.69
Debt/Equity29.85
% Insiders0.903%
Growth
Revenue Growth0.73%
Estimates
Forward P/E22.87
Forward EPS12.04
Target Mean Price308.32

DCF valuation

Model fair value for Ascendis Pharma A/S (ASND)
Result
Sign in to run the valuation for ASND.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
21 analysts · consensus Strong buy · mean target 308.32 USD (low 257.91, high 340.06) · as of 14 Nov 2026
Low 257.91
Mean 308.32
High 340.06
Price 275.39
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Ascendis Pharma A/S Logo Ascendis Pharma A/S Analysis (ASND)

Denmark Health Care Official Website Stock

Is Ascendis Pharma A/S a good investment? Ascendis Pharma A/S (ASND) is currently trading at 275.39 USD. Market analysts have a consensus price target of 308.32 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 17.53. This valuation is generally in line with the broader market.

Earnings Schedule: Ascendis Pharma A/S is expected to release its next earnings report on Feb. 10, 2027. The market consensus estimate for Forward EPS is 12.04.

Investor FAQ

Does Ascendis Pharma A/S pay a dividend?

No, it does not currently pay a dividend.

What asset class is Ascendis Pharma A/S?

Ascendis Pharma A/S is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 10, 2027. The company currently has a trailing EPS of 15.71.

Company Profile

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Exchange Ticker
NMS (United States) ASND
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion